{"title": "The efficacy of convalescent plasma for the treatment of severe influenza", "doi": "10.1101/2020.02.20.20025593", "citation_id": "2020.02.20.20025593v2", "date": "2020-02-25", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.02.20.20025593", "abstract": "<p>Background. Administration of convalescent plasma may be of clinical benefit for treatment of severe acute viral respiratory infections. However, no clear evidence exists to support or oppose convalescent plasma use in clinical practice. We conducted a systematic review and meta-analysis to assess the evidence of randomized controlled trials (RCTs) in the convalescent plasma for the treatment of severe influenza.\nMethods. Healthcare databases were searched in February 2020. All records were screened against the eligibility criteria. Data extraction and risk of bias assessments were undertaken. The primary outcome was case fatality rates by influenza.\nResults. We identified 5 RCTs of severe influenza. The pooled analyses showed no evidence for a reduction in mortality (Odds Ratio (OR) 1.06; p = 0.87; I2 = 35%). We also found non significant reductions in days in ICU and hospital, and days on mechanical ventilation. There seemed to have a biological benefit of increasing HAI titer levels and decreasing influenza B virus loads and cytokines after convalescent plasma treatment. No serious adverse events was reported between two groups. Studies were commonly of low risk of bias with high quality. \nConclusions. Convalescent plasma appears safe but may not reduce mortality in severe influenza. This therapy should be studied within the context of a well designed clinical trial for treatment of SARS Cov 2 infection.</p>", "twitter_description": "Background. Administration of convalescent plasma may be of clinical benefit for treatment of severe acute viral respiratory infections. However, no clear evidence exists to support or oppose convalescent plasma use in clinical practice. We conducted a systematic review and meta-analysis to assess the evidence of randomized controlled trials (RCTs) in the convalescent plasma for the treatment of severe influenza. Methods. Healthcare databases were searched in February 2020. All records were screened against the eligibility criteria. Data extraction and risk of bias assessments were undertaken. The primary outcome was case fatality rates by influenza. Results. We identified 5 RCTs of severe influenza. The pooled analyses showed no evidence for a reduction in mortality (Odds Ratio (OR) 1.06; p = 0.87; I2 = 35%). We also found non significant reductions in days in ICU and hospital, and days on mechanical ventilation. There seemed to have a biological benefit of increasing HAI titer levels and decreasing influenza B virus loads and cytokines after convalescent plasma treatment. No serious adverse events was reported between two groups. Studies were commonly of low risk of bias with high quality. Conclusions. Convalescent plasma appears safe but may not reduce mortality in severe influenza. This therapy should be studied within the context of a well designed clinical trial for treatment of SARS Cov 2 infection.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Clinical Trial\n\nnot application\n\n### Funding Statement\n\nNational Science and Technology Major Project (No. 2017ZX10204401); National Natural Science Foundation of China (81970071); the Special Project for Emergency of the Ministry of Science and Technology (2020YFC0841300); the Special Project of Guangdong Science and Technology Department (2020B111105001).\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nThe authors declare that all data of this study are available from the included 5 RCTs and its supplementary information files.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.20.20025593v2.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.02.20.20025593v2", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.20.20025593v2.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/25/2020.02.20.20025593.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.02.20.20025593v2", "access_rights": "restricted", "authors": ["Zhiheng Xu", "Jianmeng Zhou", "Yongbo Huang", "Xuesong Liu", "Yonghao Xu", "Sibei Chen", "Dongdong Liu", "Zhimin Lin", "Xiaoqing Liu", "Yimin Li"]}